SEC FILINGS


Form S-3ASR
ACADIA PHARMACEUTICALS INC filed this Form S-3ASR on 11/26/2018
Document Outline
Entire Document (434.4 KB)
Subdocument 1 - S-3ASR - S-3ASR
Page 1 - As filed with the Securities and Exchange Commission on November 26, 2018
Page 2 - PROSPECTUS
Page 3 - TABLE OF CONTENTS
Page 4 - ACADIA PHARMACEUTICALS INC.
Page 5 - N/A
Page 6 - RISK FACTORS
Page 7 - If we do not obtain regulatory approval of NUPLAZID for other indications in the United States, or f
Page 8 - N/A
Page 9 - NUPLAZID has only been studied in a limited number of patients and in limited populations. As we con
Page 10 - If we are unable to effectively train and equip our sales force, our ability to successfully commerc
Page 11 - Our ability to generate product revenues will be diminished if NUPLAZID does not receive coverage fr
Page 12 - Healthcare reform measures may negatively impact our ability to sell NUPLAZID or our product candida
Page 13 - N/A
Page 14 - We are subject, directly and indirectly, to federal, state and foreign healthcare laws and regulatio
Page 15 - N/A
Page 16 - If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Progr
Page 17 - The FDA granted marketing approval of NUPLAZID for the treatment of hallucinations and delusions ass
Page 18 - If we fail to obtain the capital necessary to fund our operations, we will be unable to successfully
Page 19 - The pivotal Phase 3 study with NUPLAZID for PD Psychosis, the results of which were announced in Nov
Page 20 - We do not have a partner for the development of pimavanserin, and are solely responsible for the adv
Page 21 - Delays, suspensions and terminations in our clinical trials could result in increased costs to us an
Page 22 - We previously have depended, and in the future may depend, on collaborations with third parties to d
Page 23 - We rely on third parties to conduct our clinical trials and perform data collection and analysis, wh
Page 24 - We currently depend, and in the future will continue to depend, on third parties to manufacture NUPL
Page 25 - If we are unable to attract, retain, and motivate key management, research and development, and sale
Page 26 - We have recently increased the size of our organization, and will need to continue to increase the s
Page 27 - If we fail to develop, acquire or in-license other product candidates or products, our business and
Page 28 - We expect that our results of operations will fluctuate, which may make it difficult to predict our
Page 29 - The recently passed comprehensive tax reform bill could adversely affect our business and financial
Page 30 - We may not be able to continue or fully exploit our collaborations with outside scientific and clini
Page 31 - Earthquake or fire damage to our facilities could delay our research and development efforts and adv
Page 32 - N/A
Page 33 - Confidentiality agreements with employees and others may not adequately prevent disclosure of our tr
Page 34 - N/A
Page 35 - The patent applications of pharmaceutical and biotechnology companies involve highly complex legal a
Page 36 - Risks Related to Our Industry
Page 37 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 38 - Risks Related to Our Common Stock
Page 39 - If we or our stockholders sell substantial amounts of our common stock, the market price of our comm
Page 40 - If our officers, directors, and largest stockholders choose to act together, they may be able to sig
Page 41 - We do not intend to pay dividends on our common stock in the foreseeable future; as such, you must r
Page 42 - NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 43 - USE OF PROCEEDS
Page 44 - PLAN OF DISTRIBUTION
Page 45 - LEGAL MATTERS
Page 46 - WHERE YOU CAN FIND MORE INFORMATION
Page 47 - PART II
Page 48 - Item 16. Exhibits
Page 49 - Item 17. Undertakings
Page 50 - N/A
Page 51 - SIGNATURES
Subdocument 2 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Subdocument 3 - EX-23.1 - EX-23.1
Page 1 - N/A